123 related articles for article (PubMed ID: 33832300)
1. A tolerability and safety analysis of adding granulocyte-macrophage colony-stimulating factor to local radiotherapy in a case series of seven patients with thoracic cancer.
Wang BC; Li PC; Kuang BH; Zhang ZJ; Xiao BY; Lin GH; Liu Q
Ann Palliat Med; 2021 Apr; 10(4):4193-4200. PubMed ID: 33832300
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
[TBL] [Abstract][Full Text] [Related]
3. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
Golden EB; Chhabra A; Chachoua A; Adams S; Donach M; Fenton-Kerimian M; Friedman K; Ponzo F; Babb JS; Goldberg J; Demaria S; Formenti SC
Lancet Oncol; 2015 Jul; 16(7):795-803. PubMed ID: 26095785
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib.
Qiu Y; He X; Li Z; Jiang Y; Jia Y
Ir J Med Sci; 2020 Aug; 189(3):791-797. PubMed ID: 31797203
[TBL] [Abstract][Full Text] [Related]
7. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells].
Meng FY; Xu B; Sun J; Yang Y; Niu JN
Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861
[TBL] [Abstract][Full Text] [Related]
8. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
9. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy.
Rovirosa A; Ferre J; Biete A
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):747-54. PubMed ID: 9652834
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma.
Kannan V; Bapsy PP; Anantha N; Doval DC; Vaithianathan H; Banumathy G; Reddy KB; Kumaraswamy SV; Shenoy AM
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1005-10. PubMed ID: 9169806
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
14. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
